%0 Journal Article %1 Steiner.2008 %A Steiner, E. %A Pollow, K. %A Hasenclever, Dirk %A Schormann, W. %A Hermes, M. %A Schmidt, M. %A Puhl, A. %A Brulport, M. %A Bauer, A. %A Petry, I. B. %A Koelbl, H. %A Hengstler, J. G. %D 2008 %J Gynecologic oncology %K IMISE-Publikationen %N 3 %P 569–576 %T Role of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1) for prognosis in endometrial cancer %V 108 %X BACKGROUND\r\nUrokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1) contribute to the invasiveness of many carcinomas. Here, we studied a possible association between cytosolic uPA and PA-1 concentrations in tumor tissue with prognosis in patients with endometrial cancer.\r\nMETHODS\r\nCytosolic concentrations of uPA and PAI-1 were determined in 69 primary endothelial adenocarcinomas using an enzyme-linked immunoassay (ELISA). A possible influence of uPA and PAI-1 was studied by multivariate Cox regression adjusting for the established clinical prognostic factors FIGO-stage, grading, depth of invasion, diabetes mellitus and age.\r\nRESULTS\r\nBoth uPA (p=0.011) and PAI-1 (p=0.003) were associated with relapse free time using the multivariate proportional hazards model. Association with overall survival was less pronounced with p=0.021 for uPA and p=0.358 for PAI-1. Concentrations of PAI-1 increased with FIGO stage (p=0.003) and with histological grading (p=0.005). Both uPA and PAI-1 concentrations were negatively correlated with estrogen and progesterone receptor levels.\r\nCONCLUSION\r\nThe combination of high cytosolic concentrations of uPA (>5 ng/mg total protein) and high PAI-1 (>20 ng/mg total protein) may reveal a group of patients with increased risk of progression.

@article{Steiner.2008, abstract = {BACKGROUND\r\nUrokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1) contribute to the invasiveness of many carcinomas. Here, we studied a possible association between cytosolic uPA and PA-1 concentrations in tumor tissue with prognosis in patients with endometrial cancer.\r\nMETHODS\r\nCytosolic concentrations of uPA and PAI-1 were determined in 69 primary endothelial adenocarcinomas using an enzyme-linked immunoassay (ELISA). A possible influence of uPA and PAI-1 was studied by multivariate Cox regression adjusting for the established clinical prognostic factors FIGO-stage, grading, depth of invasion, diabetes mellitus and age.\r\nRESULTS\r\nBoth uPA (p=0.011) and PAI-1 (p=0.003) were associated with relapse free time using the multivariate proportional hazards model. Association with overall survival was less pronounced with p=0.021 for uPA and p=0.358 for PAI-1. Concentrations of PAI-1 increased with FIGO stage (p=0.003) and with histological grading (p=0.005). Both uPA and PAI-1 concentrations were negatively correlated with estrogen and progesterone receptor levels.\r\nCONCLUSION\r\nThe combination of high cytosolic concentrations of uPA (>5 ng/mg total protein) and high PAI-1 (>20 ng/mg total protein) may reveal a group of patients with increased risk of progression.}, added-at = {2014-10-15T15:04:28.000+0200}, author = {Steiner, E. and Pollow, K. and Hasenclever, Dirk and Schormann, W. and Hermes, M. and Schmidt, M. and Puhl, A. and Brulport, M. and Bauer, A. and Petry, I. B. and Koelbl, H. and Hengstler, J. G.}, biburl = {https://www.bibsonomy.org/bibtex/2781e0e0ca0b04eec0d682eb3eb1d8e43/drtester}, interhash = {23c573d8ba6ae5ebf7941fbaeb5c1410}, intrahash = {781e0e0ca0b04eec0d682eb3eb1d8e43}, journal = {Gynecologic oncology}, keywords = {IMISE-Publikationen}, number = 3, pages = {569–576}, timestamp = {2014-12-03T00:00:31.000+0100}, title = {Role of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1) for prognosis in endometrial cancer}, volume = 108, year = 2008 }